Haegeun Song

Haegeun Song

Auto-generated profile, based on publicly available information

Haegeun Song

Division of Cardiology, Department of Internal Medicine, Chung-Ang University, Gwang-Myong Hospital, 14353 Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2018 in Echocardiography
Verified
Journal Article
Closed access
PDF file
HSHae Geun Song
Hae Geun Song
SKSoo‐Jin Kang
Soo‐Jin Kang
GMGary S. Mintz
Gary S. Mintz

1 August 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
YJYoung-Hoon Jeong
Young-Hoon Jeong
YOYuki Obayashi
Yuki Obayashi
HSHaegeun Song
Haegeun Song
TKTakeshi Kimura
Takeshi Kimura

9 September 2022 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
HSHaegeun Song
Haegeun Song
YKYoo Ri Kim
Yoo Ri Kim
SLSeung Eun Lee
Seung Eun Lee
HNHyewon Nam
Hyewon Nam
HKHOSEOB KIM
HOSEOB KIM
KKKyoung-Ah Kim
Kyoung-Ah Kim
Background and Objectives: Type 2 diabetes (T2D) is an independent risk factor for the development of atrial fibrillation (AF). Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have recently been shown to decrease the incidence of AF through several mechanisms, including the reduction of atrial dilatation via diuresis and the lowering of body weight. In observational studies of diabetic patients, the use of thiazolidinedione (TZD) was found to have a protective effect on new-onset AF. In this study, we aimed to compare the effect of SGLT-2i and TZD on the risk of AF in patients with T2D. Methods: We enrolled 69,122 patients newly prescribed SGLT-2i and 94,262 patients prescribed TZD from January 2014 to December 2018, using the Korean National Health Insurance Service database. We compared new-onset AF events (hospitalizations and outpatient events) in SGLT-2i and TZD groups after having taken medication for greater than 90 days. Results: During a mean follow-up of 1.8 years, 397 (0.72%) new-onset AF events occurred in the SGLT-2i group and 432 (0.79%) events in the TZD group following propensity score matching (each group n = 54,993). The hazard ratio (HR) of AF was 0.918 (95% confidence interval: 0.783–1.076, p = 0.29) in SGLT-2i-treated patients compared with TZD-treated patients. Conclusions: In this study, the risk of new-onset AF is comparable in patients treated with SGLT-2i and TZD in T2D. Either SGLT-2i or TZD would be a reasonable choice for T2D patients who are at risk for AF.